Valproic Acid Increases CD133 Positive Cells that Show Low Sensitivity to Cytostatics in Neuroblastoma

Functional interplay between MYCN, NCYM, and OCT4 promotes aggressiveness of human neuroblastomas

(2015) Yoshiki Kaneko et al.   CANCER SCIENCE

FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma

(2015) H.-Z. Lee et al.   CLINICAL CANCER RESEARCH

Histone deacetylase inhibitor valproic acid (VPA) promotes the epithelial mesenchymal transition of colorectal cancer cells via up regulation of Snail

(2015) Jutao Feng et al.   Cell Adhesion & Migration

CD133 Expression Is Not Synonymous to Immunoreactivity for AC133 and Fluctuates throughout the Cell Cycle in Glioma Stem-Like Cells

(2015) Alonso Barrantes-Freer et al.   PLoS One

Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancer

(2015) Leigh Ellis et al.   Oncotarget

Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers

(2014) Jennifer J. Wheler et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Generation of pluripotent stem cells without the use of genetic material

(2014) Akon Higuchi et al.   LABORATORY INVESTIGATION

Correlation between the prognostic value and the expression of the stem cell marker CD133 and isocitrate dehydrogenase1 in glioblastomas

(2013) Jung Ha Shin et al.   JOURNAL OF NEURO-ONCOLOGY

The Cancer Stem Cell Marker CD133 Interacts with Plakoglobin and Controls Desmoglein-2 Protein Levels

(2013) Ryo Koyama-Nasu et al.   PLoS One

Targeting Neuroblastoma Stem Cells with Retinoic Acid and Proteasome Inhibitor

(2013) Barbara Hämmerle et al.   PLoS One

Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells

(2013) Y. Wei et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CD133 Is Essential for Glioblastoma Stem Cell Maintenance

(2013) Paola Brescia et al.   STEM CELLS

The histone deacetylase inhibitor sodium valproate causes limited transcriptional change in mouse embryonic stem cells but selectively overrides Polycomb-mediated Hoxb silencing

(2013) Elsa Boudadi et al.   Epigenetics & Chromatin

Cancer stem cells: therapeutic implications and perspectives in cancer therapy

(2013) Lu Han et al.   Acta Pharmaceutica Sinica B

Characterization of the conversion between CD133+and CD133-cells in colon cancer SW620 cell line

(2012) Jian-Ming Feng et al.   CANCER BIOLOGY & THERAPY

CD133 expression is associated with poor outcome in neuroblastoma via chemoresistance mediated by the AKT pathway

(2012) Hervé Sartelet et al.   HISTOPATHOLOGY

Role of stemness-related molecules in neuroblastoma

(2012) Takehiko Kamijo   PEDIATRIC RESEARCH

Histone Deacetylase Inhibitors in Cell Pluripotency, Differentiation, and Reprogramming

(2012) Androniki Kretsovali et al.   Stem Cells International

Regenerative Effects of Mesenchymal Stem Cells: Contribution of Muse Cells, a Novel Pluripotent Stem Cell Type that Resides in Mesenchymal Cells

(2012) Shohei Wakao et al.   Cells

Oct-4+/Tenascin C+ neuroblastoma cells serve as progenitors of tumor-derived endothelial cells

(2011) Annalisa Pezzolo et al.   CELL RESEARCH

The regulatory role of histone deacetylase inhibitors in Fgf4 expression is dependent on the differentiation state of pluripotent stem cells

(2011) Guilai Shi et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Histone Deacetylase Inhibition Enhances Self Renewal and Cardioprotection by Human Cord Blood-Derived CD34+ Cells

(2011) Ilaria Burba et al.   PLoS One

Distribution of CD133 reveals glioma stem cells self-renew through symmetric and asymmetric cell divisions

(2011) J D Lathia et al.   Cell Death & Disease

The AC133 Epitope, but not the CD133 Protein, Is Lost upon Cancer Stem Cell Differentiation

(2010) K. Kemper et al.   CANCER RESEARCH

Valproic Acid in the Complex Therapy of Malignant Tumors

(2010) J. Hrebackova et al.   CURRENT DRUG TARGETS

Molecular and Therapeutic Potential and Toxicity of Valproic Acid

(2010) Sébastien Chateauvieux et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Human neuroblastoma cells withMYCNamplification are selectively resistant to oxidative stress by transcriptionally up-regulating glutamate cysteine ligase

(2010) Miguel Veas-Perez de Tudela et al.   JOURNAL OF NEUROCHEMISTRY

Both CD133+and CD133−subpopulations of A549 and H446 cells contain cancer-initiating cells

(2009) Xiangjiao Meng et al.   CANCER SCIENCE

The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer

(2009) David Horst et al.   JOURNAL OF PATHOLOGY

Resistance of stem-like cells from neuroblastoma cell lines to commonly used chemotherapeutic agents

(2009) Sharada D. Vangipuram et al.   PEDIATRIC BLOOD & CANCER

CD133 (Prominin) Negative Human Neural Stem Cells Are Clonogenic and Tripotent

(2009) Yirui Sun et al.   PLoS One

Sox2 and Oct-3/4: a versatile pair of master regulators that orchestrate the self-renewal and pluripotency of embryonic stem cells

(2009) Angie Rizzino   Wiley Interdisciplinary Reviews-Systems Biology and Medicine

Abnormal DNA Methylation of CD133 in Colorectal and Glioblastoma Tumors

(2008) J. M. Yi et al.   CANCER RESEARCH

Promoter hypomethylation regulates CD133 expression in human gliomas

(2008) Kouichi Tabu et al.   CELL RESEARCH

Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells

(2008) T Baba et al.   ONCOGENE

Detection and Characterization of CD133+ Cancer Stem Cells in Human Solid Tumours

(2008) Virginia Tirino et al.   PLoS One

CD133 Is a Marker of Bioenergetic Stress in Human Glioma

(2008) Corinne E. Griguer et al.   PLoS One